Sign Up to like & get
recommendations!
0
Published in 2018 at "Diagnostic Cytopathology"
DOI: 10.1002/dc.23900
Abstract: Pembrolizumab was recently approved as a first line agent for metastatic NSCLC in patients with high programmed death‐ligand 1 (PD‐L1) expression.
read more here.
Keywords:
ligand expression;
programmed death;
death ligand;
Sign Up to like & get
recommendations!
2
Published in 2023 at "Thoracic cancer"
DOI: 10.1111/1759-7714.14922
Abstract: BACKGROUND Identifying the preoperative risk factors for lymph node upstaging could contribute to the development of individualized perioperative treatment for patients with non-small cell lung cancer (NSCLC). The current study aimed to evaluate the risk…
read more here.
Keywords:
programmed death;
ligand expression;
death ligand;
Sign Up to like & get
recommendations!
0
Published in 2017 at "Journal of Cutaneous Pathology"
DOI: 10.1111/cup.12876
Abstract: Nivolumab is a programmed cell death receptor‐1 (PD‐1) antibody used in the treatment of metastatic or unresectable melanoma. Cutaneous reactions are the most common adverse events reported with these agents and are rarely severe or…
read more here.
Keywords:
death;
ligand expression;
death ligand;
programmed cell ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2022 at "Journal of immunology"
DOI: 10.4049/jimmunol.2101166
Abstract: γδ T cells reside at mucosal and epithelial barriers, and they often accumulate at sites of inflammation, both infectious and autoimmune, as well as in certain tumors. However, progress in understanding their function is considerably…
read more here.
Keywords:
synovial cell;
mitochondrial reactive;
ligand expression;
expression ... See more keywords